Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

celebratelife Jul. 30 at 3:34 PM

$KPTI Shareholder-Funded Value-Destroyer KaryoFUN "Vacation-Club" [Update 2] https://x.com/karyowatch/status/1950580436981133761

0 · Reply

celebratelife Jul. 30 at 5:08 AM

$KPTI Shareholder-Funded KaryoFUN Vacation-Club Called "Work" [Updated]. https://x.com/karyowatch/status/1950422890437808321

0 · Reply

okhello1 Jul. 29 at 7:17 PM

$KPTI This is CLVS II.

0 · Reply

profDB Jul. 28 at 11:59 AM

$KPTI https://finance.yahoo.com/news/antengene-announces-xpovio-approved-china-104900939.html

0 · Reply

BiotechBonesaw Jul. 27 at 1:51 PM

$KPTI good news for Karyopharm? 😂

1 · Reply

katanare Jul. 24 at 5:53 PM

$IOVA Drying up the float — classic biotech strategy. Before key catalysts, they wipe out weak hands so no sellers block the move. Controlled selling + absorption = full control before news. This already happened with: • $IMMU (Gilead acquisition) • $SRPT (FDA agreement) • $KPTI, $TCRT, $CLVS (pre-PR or squeeze) Catalyst + float control = explosive setup.

3 · Reply

nacho217 Jul. 24 at 4:53 PM

$KPTI

0 · Reply

celebratelife Jul. 23 at 10:13 PM

$KPTI Any way you look at it a 25% gain in a day can't be a bad thing. We just need 5 more just to get to $1 pre-RS ($15) and a lot more to get to where the stock was before Paulson and the rest of these value destroyer incompetent dorks on the Board destroy KPTI. Bring on more 25% days!!

0 · Reply

celebratelife Jul. 23 at 6:35 PM

$KPTI the biggest trades are showing as red, though I haven't seen time and sale. The crooks often run it up to continue shorting. Key metric will be if short interest starts decreasing. It's ballooned since the RSS, as we expected but management just ignored our warnings: without fundamental change RSS leads to further drop, and they didn't change and kept the same lousy CEO.

1 · Reply

_www_larval_com_ Jul. 23 at 5:02 PM

$KPTI has shot 7% higher to 23% (~304Kv) a few minutes ago, 08/15 options, follow for more volatility.

0 · Reply

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2025, 8:00 AM EDT - 2 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 2 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 2 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 13, 2025, 1:39 PM EDT - 2 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 7:15 AM EDT - 2 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 2 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 2 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 5, 2025, 12:00 AM EST - 5 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 5 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 11:05 AM EST - 5 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:30 AM EST - 5 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 5 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 6 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 7 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 7 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 9, 2024, 8:00 AM EST - 8 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 3, 2024, 7:00 AM EST - 8 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 8 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 8 months ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 9 months ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:22 PM EST - 9 months ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:30 PM EST - 9 months ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 AM EST - 9 months ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 9 months ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 7:30 AM EDT - 9 months ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 9 months ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 10 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 11 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 3, 2024, 7:00 AM EDT - 11 months ago

Karyopharm to Participate at Upcoming Investor Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 2, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 30, 2024, 2:28 PM EDT - 1 year ago

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Mar 6, 2024, 4:05 PM EST - 1 year ago

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Feb 29, 2024, 11:26 AM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Feb 22, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Feb 5, 2024, 12:26 PM EST - 1 year ago

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Jan 8, 2024, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

celebratelife Jul. 30 at 3:34 PM

$KPTI Shareholder-Funded Value-Destroyer KaryoFUN "Vacation-Club" [Update 2] https://x.com/karyowatch/status/1950580436981133761

0 · Reply

celebratelife Jul. 30 at 5:08 AM

$KPTI Shareholder-Funded KaryoFUN Vacation-Club Called "Work" [Updated]. https://x.com/karyowatch/status/1950422890437808321

0 · Reply

okhello1 Jul. 29 at 7:17 PM

$KPTI This is CLVS II.

0 · Reply

profDB Jul. 28 at 11:59 AM

$KPTI https://finance.yahoo.com/news/antengene-announces-xpovio-approved-china-104900939.html

0 · Reply

BiotechBonesaw Jul. 27 at 1:51 PM

$KPTI good news for Karyopharm? 😂

1 · Reply

katanare Jul. 24 at 5:53 PM

3 · Reply

nacho217 Jul. 24 at 4:53 PM

$KPTI

0 · Reply

celebratelife Jul. 23 at 10:13 PM

0 · Reply

celebratelife Jul. 23 at 6:35 PM

1 · Reply

_www_larval_com_ Jul. 23 at 5:02 PM

$KPTI has shot 7% higher to 23% (~304Kv) a few minutes ago, 08/15 options, follow for more volatility.

0 · Reply

celebratelife Jul. 22 at 5:56 PM

$KPTI Legally Liable Destroyers of Karyopharm: https://x.com/karyowatch/status/1947716915700392028

0 · Reply

celebratelife Jul. 21 at 10:33 PM

$KPTI ABOUT CHIEF IDIOT & VALUE DESTROYER https://x.com/karyowatch/status/1947424557893358045

0 · Reply

celebratelife Jul. 21 at 10:19 PM

$KPTI Biggest Biotech Idiots Selfserving Dream Team For Shorts https://x.com/karyowatch/status/1947421140600951031

0 · Reply

wildcard55 Jul. 20 at 8:09 PM

$KPTI

1 · Reply

BiotechBonesaw Jul. 20 at 7:35 PM

$ALT @wildcard55 could you also post one of these for $KPTI shareholders with Paulson instead of Garg? 😂 They would appreciate this much moreso

0 · Reply

celebratelife Jul. 20 at 6:44 PM

$KPTI LIABILITY & ACCOUNTABILITY https://x.com/karyowatch/status/1947004669605138439

0 · Reply

celebratelife Jul. 19 at 11:19 PM

$KPTI Wicked Self-Serving Inept Wasteful Or Compromised CEO Richard Paulson wasting our money on plush trip to California https://x.com/karyowatch/status/1946711143965192488

0 · Reply

celebratelife Jul. 19 at 10:56 PM

$KPTI

0 · Reply

celebratelife Jul. 19 at 7:06 PM

$KPTI I also asked ChatGPT what it thinks!

1 · Reply

celebratelife Jul. 19 at 7:01 PM

$KPTI ETHICAL SHORTCOMINGS OF KARYOPHARM CEO AND BOARD MEMBERS https://x.com/karyowatch/status/1946646470351896883

0 · Reply

BiotechBonesaw Jul. 19 at 1:09 AM

$KPTI I asked ChatGPT if Karyopharm will declare bankruptcy like $CLVSQ did. It’s not looking good

0 · Reply

celebratelife Jul. 18 at 10:14 PM

$KPTI THE EVIL CEO / BOARD MAKING A KILLING AT OUR COST! https://x.com/karyowatch/status/1946332295972990996

0 · Reply

Market Cap	37.76M
Revenue (ttm)	145.24M
Net Income (ttm)	-76.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.62%
Debt to Equity Ratio	-0.58

Volume	39,554
Avg Vol	129,292
Day's Range	N/A - N/A
Shares Out	8.64M
Stochastic %K	27%
Beta	0.24
Analysts	Strong Sell
Price Target	$21.60